A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Finding, Parallel Group Study to Assess Efficacy and Safety of PF-07081532, and Open-Label Oral Semaglutide, in Adults with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled

Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus® in People With Type 2 Diabetes Mellitus and Separately PF-07081532 in People with Obesity

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Finding, Parallel Group Study to Assess Efficacy and Safety of PF-07081532, and Open-Label Oral Semaglutide, in Adults with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Metformin, and Separately PF-07081532 Compared to Matching Placebo in Adults with Obesity but Without T2DM

Category & Conditions: Diabetes and Metabolic Disorders

Medicine: PF-07081532

ClinicalTrials.gov Identifier (NCT): NCT05579977

Protocol ID: C3991004

Print Download

Open Plain Language Summary Result: Click here